Related Experiment Video
Updated: May 19, 2026
12:03
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Angiotensin converting enzyme 2 and atherosclerosis.
Yutang Wang1, Chris Tikellis, Merlin C Thomas
1The Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, James Cook University, Townsville, Queensland 4811, Australia.
Atherosclerosis
|September 6, 2012
Summary
Angiotensin converting enzyme 2 (ACE2) protects against atherosclerosis by degrading harmful angiotensin II and producing beneficial angiotensin 1-7. This enzyme plays a crucial role in regulating the renin-angiotensin system and preventing disease progression.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Renal Physiology
Background:
- The renin-angiotensin system (RAS) regulates blood pressure and fluid balance.
- Angiotensin II, a key RAS component, promotes atherosclerosis.
- Angiotensin converting enzyme 2 (ACE2) was identified in 2000, offering new insights into RAS regulation.
Purpose of the Study:
- To review the protective role of ACE2 against atherosclerosis in experimental models and humans.
- To examine ACE2's involvement in various cell types relevant to atherosclerosis.
- To explore the cellular and molecular mechanisms underlying ACE2's atheroprotective effects.
Main Methods:
- Literature review of studies on ACE2 and atherosclerosis.
- Analysis of experimental animal models of atherosclerosis.
- Examination of cellular and molecular mechanisms.
Main Results:
- ACE2 degrades pro-atherosclerotic angiotensin II.
- ACE2 generates anti-atherosclerotic angiotensin 1-7.
- ACE2 shifts the RAS balance, inhibiting atherosclerosis progression in animal models.
Conclusions:
- ACE2 plays a significant protective role in preventing atherosclerosis.
- Understanding ACE2's mechanisms offers therapeutic potential for cardiovascular diseases.
- ACE2 represents a key target for modulating RAS activity to combat atherosclerosis.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...